Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404 · see citing works

Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria

Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047 · see citing works

Vascular dementia: Diagnostic criteria for research studies: Report of the NINDS‐AIREN International Workshop*

Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921 · see citing works

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop

McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960 · see citing works

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481 · see citing works

Primary Progressive Aphasia

Weıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,012 · see citing works

DECLARATION OF HELSINKI.

Gandevia, B., & Tovell, A. (1964) · PubMed · Cited by 2,068 · see citing works

A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau

Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 1× · see citing works

A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity

Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., et al. (2001) · Nature · doi:10.1038/35102591 · Cited by 1,388 · see citing works

Improved discrimination of AD patients using β-amyloid _(1-42) and tau levels in CSF

Hulstaert, F., Blennow, K., Ivanoiu, A., Schoonderwaldt, H. C., Riemenschneider, M., Deyn, P. P. D., Bancher, C., Cras, P., Wiltfang, J., Mehta, P. D., et al. (1999) · Neurology · doi:10.1212/wnl.52.8.1555 · Cited by 724 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works

Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

Vanmechelen, E., Vanderstichele, H., Davidsson, P., Kerschaver, E. V., Perre, B. V. D., Sjögren, M. J. C., Andreasen, N. C., & Blennow, K. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01036-3 · Cited by 487 · see citing works

Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosisof Alzheimer Disease: A Comparative Cerebrospinal Fluid Study

Hampel, H., Buerger, K., Zinkowski, R., Teipel, S. J., Goernitz, A., Andreasen, N., Sjoegren, M., DeBernardis, J., Kerkman, D., Ishiguro, K., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.1.95 · Cited by 434 · see citing works

Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340 · see citing works

Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau

Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M., Henkel, A. W., Henkel, M. K., Eikenberg, O., Antz, C., Krause, W., Reulbach, U., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00086-1 · Cited by 309 · see citing works

Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

Wiltfang, J., Esselmann, H., Bibl, M., Av, S., Otto, M., Paul, S., Schmidt, B., Klafki, H., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 268 · see citing works

Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho‐Tau in patients with low‐ and high‐CSF Aβ40 load

Wiltfang, J., Esselmann, H., Bibl, M., Hüll, M., Hampel, H. J., Kessler, H., Frölich, L., Schröder, J., Peters, O., Jessen, F., et al. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04404.x · Cited by 263 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works

CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia

Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Klafki, H., Sparbier, K., Av, S., Cepek, L., Trenkwalder, C., Rüther, E., et al. (2006) · Brain · doi:10.1093/brain/awl063 · Cited by 209 · see citing works

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42

Maddalena, A., Papassotiropoulos, A., Müller-Tillmanns, B., Jung, H. H., Hegi, T., Nitsch, R. M., & Hock, C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1202 · Cited by 204 · see citing works

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid β Peptides

Lewczuk, P., Beck, G., Esselmann, H., Bruckmoser, R., Zimmermann, R., Fiszer, M., Bibl, M., Maler, J. M., Kornhuber, J., & Wiltfang, J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.058776 · Cited by 143 · see citing works

Elevation of β-Amyloid Peptide 2–42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells

Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M., Kretzschmar, H. A., Beyermann, M., Schleuder, D., Jahn, H., Rüther, E., Kornhuber, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102790200 · Cited by 126 · see citing works

Clinical Guidelines for Idiopathic Normal Pressure Hydrocephalus

Ishikawa, M. (2004) · Neurologia medico-chirurgica · doi:10.2176/nmc.44.222 · Cited by 124 · see citing works

Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?

Schoonenboom, N. S. M., Mulder, C., van Kamp, G. J., Mehta, S. P., Scheltens, P., Blankenstein, M. A., & Mehta, P. D. (2005) · Annals of Neurology · doi:10.1002/ana.20508 · Cited by 120 · see citing works

The amyloid‐ β (A β ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A β peptide

Lewczuk, P., Esselmann, H., Meyer, M., Wollscheid, V., Neumann, M., Otto, M., Maler, J. M., Rüther, E., Kornhuber, J., & Wiltfang, J. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.1048 · Cited by 100 · see citing works

Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia

de Jong, D., Jansen, R. W. M. M., Kremer, B. P. H., & Verbeek, M. M. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.7.755 · Cited by 98 · see citing works

CSF diagnosis of Alzheimer’s disease and dementia with Lewy bodies

Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P., Trenkwalder, C., Brechlin, P., Rüther, E., Kornhuber, J., Otto, M., & Wiltfang, J. (2006) · Journal of neural transmission · doi:10.1007/s00702-006-0537-z · Cited by 92 · see citing works

Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier‐mediated epitope masking of amyloid β peptides

Bibl, M., Esselmann, H., Otto, M., Lewczuk, P., Cepek, L., Rüther, E., Kornhuber, J., & Wiltfang, J. (2004) · Electrophoresis · doi:10.1002/elps.200305992 · Cited by 91 · see citing works

Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias

Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H., Wolf, S., Trenkwalder, C., Otto, M., Stiens, G., Rüther, E., Kornhuber, J., et al. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001967 · Cited by 90 · see citing works

Selective pathological changes of the periaqueductal gray matter in Alzheimer's disease

Parvizi, J., Hoesen, G. W. V., & Damásio, A. R. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 70 · see citing works

New criteria for the diagnosis of vascular dementia

Drachman, D. A. (1993) · Neurology · doi:10.1212/wnl.43.2.243 · Cited by 57 · see citing works

The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently

Shoji, M., Kanai, M., Matsubara, E., Tomidokoro, Y., Shizuka, M., Ikeda, Y., Ikeda, M., Harigaya, Y., Okamoto, K., & Hirai, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00229-3 · Cited by 50 · see citing works

Progressive Supranuclear Palsy and Corticobasal Degeneration

Lessig, S., & Litvan, I. (2014) · Oxford University Press eBooks · doi:10.1093/med/9780199928453.003.0011 · Cited by 36 · see citing works

Reduced CSF carboxyterminally truncated Aβ peptides in frontotemporal lobe degenerations

Bibl, M., Mollenhauer, B., Wolf, S., Esselmann, H., Lewczuk, P., Kornhuber, J., & Wiltfang, J. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-006-0618-z · Cited by 33 · see citing works

Progressive Supranuclear Palsy and Corticobasal Degeneration

Coughlin, D. G., Dickson, D. W., Josephs, K. A., & Litvan, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_11 · Cited by 32 · see citing works

Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness

Shoji, M., & Kanai, M. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3306 · Cited by 31 · see citing works

CSF amyloid‐β 1‐38 and 1‐42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction

Bibl, M., Lewczuk, P., Esselmann, H., Mollenhauer, B., Klafki, H., Welge, V., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2008) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200800006 · Cited by 27 · see citing works

Cerebrospinal Fluid Neurochemical Phenotypes in Vascular Dementias: Original Data and Mini-Review

Bibl, M., Mollenhauer, B., Esselmann, H., Schneider, M., Lewczuk, P., Welge, V., Gross, M., Falkai, P., Kornhuber, J., & Wiltfang, J. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000115975 · Cited by 26 · see citing works

Increased Cerebrospinal Fluid Aβ38/Aβ42 Ratio in Alzheimer Disease

Mehta, P. D., & Pirttilä, T. (2005) · Neurodegenerative Diseases · doi:10.1159/000090363 · Cited by 24 · see citing works

The TAPS project 40: quality of care provisions for the elderly mentally ill?traditional vs alternative facilities

Wills, W., Trieman, N., & Leff, J. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199804)13:4

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works

Alzheimer's disease

Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994 · see citing works

Total and phosphorylated tau protein as biological markers of Alzheimer’s disease

Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389 · see citing works

GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease

Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383 · see citing works

Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works

Truncated and modified amyloid-beta species

Kummer, M. P., & Heneka, M. T. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt258 · Cited by 338 · see citing works

Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 332 · see citing works

Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers

Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253 · see citing works

MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid

Müller, M., Kuiperij, H. B., Claassen, J. A. H. R., Küsters, B., & Verbeek, M. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.005 · Cited by 234 · see citing works

Conformations and Biological Activities of Amyloid Beta Peptide 25-35

Millucci, L., Ghezzi, L., Bernardini, G., & Santucci, A. (2010) · Current Protein and Peptide Science · doi:10.2174/138920310790274626 · Cited by 195 · see citing works

Diagnostic and therapeutic potential of exosomes in Alzheimer’s disease

Martins, T. S., Trindade, D., Vaz, M., Campelo, I., Almeida, M., Trigo, G., Silva, O. A. B. D. C. E., & Henriques, A. G. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15112 · Cited by 174 · see citing works

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B. G., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159 · see citing works

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P

Koopman, K., Bastard, N. L., Martin, J., Nagels, G., Deyn, P. P. D., & Engelborghs, S. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.02.017 · Cited by 151 · see citing works

Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid-β1–42 and τ Proteins as Alzheimer Disease Biomarkers

Kang, J., Korecka, M., Toledo, J. B., Trojanowski, J. Q., & Shaw, L. M. J. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2013.202937 · Cited by 146 · see citing works

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 141 · see citing works

Alzheimer’s Retinopathy: Seeing Disease in the Eyes

Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 130 · see citing works

Genetic architecture of Alzheimer's disease

Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126 · see citing works

The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers

Wallon, D., The collaborators of the GMAJ project, Rousseau, S., Rovelet‐Lecrux, A., Quillard‐Muraine, M., Guyant‐Maréchal, L., Martinaud, O., Pariente, J., Puel, M., Rollin‐Sillaire, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120172 · Cited by 124 · see citing works

CSF biomarkers for Alzheimer's disease: current utility and potential future use

Holtzman, D. M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.003 · Cited by 122 · see citing works

Quantitation of amyloid beta peptides Aβ1–38, Aβ1–40, and Aβ1–42 in human cerebrospinal fluid by ultra-performance liquid chromatography–tandem mass spectrometry

Lame, M. E., Chambers, E. E., & Blatnik, M. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.08.010 · Cited by 123 · see citing works

Performance of Aβ1-40, Aβ1-42, Total Tau, and Phosphorylated Tau as Predictors of Dementia in a Cohort of Patients with Mild Cognitive Impairment

Parnetti, L., Chiasserini, D., Eusebi, P., Giannandrea, D., Bellomo, G., Carlo, C. D., Padiglioni, C., Mastrocola, S., Lisetti, V., & Calabresi, P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111349 · Cited by 109 · see citing works

Diagnostic Accuracy of Cerebrospinal Fluid Amyloid-β Isoforms for Early and Differential Dementia Diagnosis

Struyfs, H., Broeck, B. V., Timmers, M., Fransén, E., Sleegers, K., Broeckhoven, C. V., Deyn, P. P. D., Streffer, J. R., Mercken, M. H., & Engelborghs, S. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141986 · Cited by 104 · see citing works

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 100 · see citing works

Aggregation of Disordered Proteins Associated with Neurodegeneration

Tsoi, P. S., Quan, M. D., Ferreon, J. C., & Ferreon, A. C. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043380 · Cited by 97 · see citing works

Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease

Jentsch, S., Schweitzer, D., Schmidtke, K., Peters, S., Dawczynski, J., Bär, K., & Hammer, M. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12609 · Cited by 96 · see citing works

Cerebrospinal Fluid Aβ to Tau Ratio and Postoperative Cognitive Change

Xie, Z., McAuliffe, S., Swain, C. A., Ward, S. A. P., Crosby, C. A., Zheng, H., Sherman, J. C., Dong, Y., Zhang, Y., Sunder, N., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318298b077 · Cited by 91 · see citing works

Investigation of the Molecular Role of Brain-Derived Neurotrophic Factor in Alzheimer’s Disease

Girotra, P., Behl, T., Sehgal, A., Singh, S., & BUNGAU, S. G. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01824-8 · Cited by 89 · see citing works

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

Mattsson, N., Blennow, K., & Zetterberg, H. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.131 · Cited by 86 · see citing works

Particulate Matter Exposure Exacerbates Amyloid-β Plaque Deposition and Gliosis in APP/PS1 Mice

Sahu, B., Mackos, A. R., Floden, A. M., Wold, L. E., & Combs, C. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200919 · Cited by 86 · see citing works

Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers

Lewczuk, P., Zimmermann, R., Wiltfang, J., & Kornhuber, J. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0277-y · Cited by 86 · see citing works

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 85 · see citing works

An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease

Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 87 · see citing works

Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid

Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P. M., Tholance, Y., Quadrio, I., Tiers, L., Gor, B., Chaulet, C., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.022 · Cited by 78 · see citing works

Alzheimer’s Disease: A Clinical Practice-Oriented Review

Alves, L., Correia, A. S., Miguel, R., Alegria, P., & Bugalho, P. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00063 · Cited by 69 · see citing works

Single-step immunoassays and microfluidic droplet operation: Towards a versatile approach for detection of amyloid-β peptide-based biomarkers of Alzheimer’s disease

Mai, T. D., Ferraro, D., Aboud, N., Renault, R., Serra, M., Tran, N. T., Viovy, J., Smadja, C., Descroix, S., & Taverna, M. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.09.003 · Cited by 68 · see citing works

Biomarkers in translational research of Alzheimer’s Disease

Tarawneh, R., & Holtzman, D. M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.04.006 · Cited by 67 · see citing works

Decreased sAβPPβ, Aβ 38 , and Aβ 40 Cerebrospinal Fluid Levels in Frontotemporal Dementia

Gabelle, A., Roche, S., Gény, C., Bennys, K., Labauge, P. M., Tholance, Y., Quadrio, I., Tiers, L., Gor, B., Boulanghien, J., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110515 · Cited by 67 · see citing works

The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers

Benítez, B. A., Karch, C. M. M., Cai, Y., Jin, S. C., Cooper, B., Carrell, D., Bertelsen, S. E., Chibnik, L. B., Schneider, J. A., Bennett, D., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003685 · Cited by 64 · see citing works

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals

Lehmann, S., Dumurgier, J., Ayrignac, X., Marelli, C., Alcolea, D. A., Fortea, J., Thouvenot, É., Delaby, C., Hirtz, C., Vialaret, J., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00696-1 · Cited by 62 · see citing works

Serum IL‐8 is a marker of white‐matter hyperintensities in patients with Alzheimer's disease

Zhu, Y., Chai, Y. L., Hilal, S., Ikram, M. K., Venketasubramanian, N., Wong, B., Chen, C., & Lai, M. K. P. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.001 · Cited by 61 · see citing works

Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?

Struyfs, H., Hecke, W. V., Veraart, J., Sijbers, J., Slaets, S., Belder, M. D., Wuyts, L. L., Peters, B., Sleegers, K., Robberecht, C., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150253 · Cited by 61 · see citing works

Neuroimaging and Biochemical Markers in the Three Variants of Primary Progressive Aphasia

Gil‐Navarro, S., Lladó, A., Rami, L., Castellvı́, M., Bosch, B., Bargalló, N., Lomeña, F., Reñé, R., Montagut, N., Antonell, A., et al. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000346289 · Cited by 60 · see citing works

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

Bibl, M., Gallus, M., Welge, V., Esselmann, H., Wolf, S., Rüther, E., & Wiltfang, J. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0801-3 · Cited by 59 · see citing works

Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders

Nutu, M., Zetterberg, H., Londos, E., Minthon, L., Nägga, K., Blennow, K., Hansson, O., & Öhrfelt, A. (2013) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000353442 · Cited by 57 · see citing works

Dissecting IWG-2 typical and atypical Alzheimer’s disease: insights from cerebrospinal fluid analysis

Paterson, R. W., Toombs, J., Slattery, C. F., Nicholas, J. M., Andréasson, U., Magdalinou, N. K., Blennow, K., Warren, J. D., Mummery, C. J., Rossor, M. N., et al. (2015) · Journal of Neurology · doi:10.1007/s00415-015-7904-3 · Cited by 56 · see citing works

CSF amyloid  38 as a novel diagnostic marker for dementia with Lewy bodies

Mulugeta, E., Londos, E., Ballard, C., Alves, G., Zetterberg, H., Blennow, K., Skogseth, R., Minthon, L., & Aarsland, D. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199398 · Cited by 54 · see citing works

Plasma amyloid-β levels, cerebral atrophy and risk of dementia: a population-based study

Hilal, S., Wolters, F. J., Verbeek, M. M., Vanderstichele, H., Ikram, M. K., Stoops, E., Ikram, M. A., & Vernooij, M. W. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0395-6 · Cited by 52 · see citing works

Clinical significance of fluid biomarkers in Alzheimer’s Disease

Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00107-0 · Cited by 53 · see citing works

The Aβ(1–38) peptide is a negative regulator of the Aβ(1–42) peptide implicated in Alzheimer disease progression

Quartey, M. O., Nyarko, J. N. K., Maley, J. M., Barnes, J. R., Bolanos, M. A. C., Heistad, R. M., Knudsen, K. J., Pennington, P. R., Buttigieg, J. A., de Carvalho, C. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80164-w · Cited by 53 · see citing works

Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis

Struyfs, H., Niemantsverdriet, E., Goossens, J., Fransén, E., Martin, J., Deyn, P. P. D., & Engelborghs, S. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00138 · Cited by 52 · see citing works

Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: Change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau

Ray, B., Reyes, P. F., & Lahiri, D. K. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.07.011 · Cited by 51 · see citing works

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer’s disease

Adamczuk, K., Schaeverbeke, J. M., Vanderstichele, H., Lilja, J., Nelissen, N., Laere, K. V., Dupont, P. J., Hilven, K., Poesen, K., & Vandenberghe, R. R. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0159-5 · Cited by 49 · see citing works

Novel Exosome Biomarker Candidates for Alzheimer’s Disease Unravelled Through Mass Spectrometry Analysis

Martins, T. S., Marçalo, R., Silva, C. B. D. C. E., Trindade, D., Catita, J. A. M., Amado, F. M. L., Melo, T., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02762-1 · Cited by 46 · see citing works

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 46 · see citing works

Alzheimer CSF biomarkers in routine clinical setting

Tabaraud, F., Leman, J. P., Milor, A.-M., Roussie, J. M., Barrière, G., Tartary, M., Boutros-Toni, F., & Rigaud, M. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01592.x · Cited by 44 · see citing works

A New Version of Grain-128 with Authentication

Ågren, M., Hell, M., Johansson, T., & Meier, W. (2011) · Lund University Publications (Lund University) · Cited by 43 · see citing works

Alzheimer’s Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint

Alawode, D. O. T., Fox, N. C., Zetterberg, H., & Heslegrave, A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.837390 · Cited by 40 · see citing works

Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment

Sierra, A., Balasa, M., Olives, J., Antonell, A., Iranzo, Á., Castellvı́, M., Bosch, B., Grau‐Rivera, O., Fernández‐Villullas, G., Rami, L., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000439258 · Cited by 40 · see citing works

Performance Evaluation of an Automated ELISA System for Alzheimer’s Disease Detection in Clinical Routine

Chiasserini, D., Biscetti, L., Farotti, L., Eusebi, P., Salvadori, N., Lisetti, V., Baschieri, F., Chipi, E., Frattini, G., Stoops, E., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160298 · Cited by 40 · see citing works

Potential of FTIR Spectroscopy Applied to Exosomes for Alzheimer’s Disease Discrimination: A Pilot Study

Martins, T. S., Magalhães, S., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., Delgadillo, I., Catita, J. A. M., Silva, O. A. B. D. C. E., Nunes, A., & Henriques, A. G. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191034 · Cited by 40 · see citing works

APP mutations in the Aβ coding region are associated with abundant cerebral deposition of Aβ38

Moro, M. L., Giaccone, G., Lombardi, R., Indaco, A., Uggetti, A., Morbin, M., Saccucci, S., Fede, G. D., Catania, M., Walsh, D. M., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1061-x · Cited by 39 · see citing works

Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment

Balasa, M., Sánchez‐Valle, R., Antonell, A., Bosch, B., Olives, J., Rami, L., Castellvı́, M., Molinuevo, J. L., & Lladó, A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132195 · Cited by 38 · see citing works

Molecular Diagnostics of Calcineurin-Related Pathologies

Musson, R. E. A., Cobbaert, C. M., & Smit, N. P. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.167296 · Cited by 37 · see citing works

Magneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation

Mai, T. D., Pereiro, I., Hiraoui, M., Viovy, J., Descroix, S., Taverna, M., & Smadja, C. (2015) · The Analyst · doi:10.1039/c5an01179e · Cited by 36 · see citing works

Depressive disorders in the elderly and dementia: An update

Dias, N. S., Barbosa, I. G., Kuang, W., & Teixeira, A. L. (2020) · Dementia & Neuropsychologia · doi:10.1590/1980-57642020dn14-010001 · Cited by 33 · see citing works

Aβ38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models

Reinert, J., Martens, H., Hüttenrauch, M., Kolbow, T., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Bayer, T. A., & Wirths, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131373 · Cited by 33 · see citing works

Biomarkers of Alzheimer’s disease in severe obstructive sleep apnea–hypopnea syndrome in the Chinese population

Kong, W., Zheng, Y., Xu, W., Gu, H., & Wu, J. (2020) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-020-05948-2 · Cited by 31 · see citing works

Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review

Chaudhry, A., Houlden, H., & Rizig, M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116886 · Cited by 30 · see citing works

Amyloid-β as a biomarker for Alzheimer’s disease: quantification methods in body fluids

Galozzi, S., Marcus, K., & Barkovits, K. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1065183 · Cited by 30 · see citing works

Mass spectrometry is a multifaceted weapon to be used in the battle against Alzheimer's disease: Amyloid beta peptides and beyond

Grasso, G. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21566 · Cited by 30 · see citing works

Tau in Late-Life Depression: A Systematic Review and Meta-Analysis

Brown, E. E., Iwata, Y., Chung, J. K., Gerretsen, P., & Graff-Guerrero, A. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160401 · Cited by 29 · see citing works

Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer’s disease and other neurodegenerative dementias

Genius, J., Klafki, H., Benninghoff, J., Esselmann, H., & Wiltfang, J. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0362-3 · Cited by 28 · see citing works

Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea

Park, S. A., Chae, W. S., Kim, H. J., Shin, H. S., Kim, S., Im, J. Y., Ahn, S. I., Min, K. D., Yim, S. J., Ye, B. S., et al. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000184 · Cited by 28 · see citing works

DW14006 as a direct AMPKα1 activator improves pathology of AD model mice by regulating microglial phagocytosis and neuroinflammation

Lv, J., Wang, W., Zhu, X., Xu, X., Yan, Q., Lu, J., Shi, X., Wang, Z., Zhou, J., Huang, X., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.07.041 · Cited by 28 · see citing works

The Potential Roles of Exosomes Carrying APP and Tau Cleavage Products in Alzheimer’s Disease

Zhao, Y., Gu, Y., Zhang, Q., Liu, H., & Liu, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051883 · Cited by 28 · see citing works

Patchouli alcohol as a selective estrogen receptor β agonist ameliorates AD-like pathology of APP/PS1 model mice

Yan, Q., Lv, J., Shen, X., Yang, J., Yang, J.-Z., Nie, R.-F., Lu, J., Huang, Y.-J., Wang, J.-Y., & Shen, X. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00857-4 · Cited by 25 · see citing works

Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries

Xu, X., Kwon, J., Yan, R., Apio, C., Song, S. C., Heo, G., Yang, Q., Timsina, J., Liu, M., Budde, J., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0562 · Cited by 26 · see citing works

cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases

Spitzer, P., Klafki, H., Blennow, K., Buée, L., Esselmann, H., Herukka, S., Jiménez, C. R., Klivènyi, P., Lewczuk, P., Maler, J. M., et al. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/548145 · Cited by 24 · see citing works

Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia

Sonnen, J. A., Montine, K. S., Quinn, J. F., Breitner, J. C. S., & Montine, T. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1236 · Cited by 23 · see citing works

Clinical phenotypes and genetic biomarkers of FTLD

Galimberti, D., & Scarpini, E. A. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0804-0 · Cited by 22 · see citing works

sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study

Butts, B., Huang, H., Hu, W. T., Kehoe, P. G., Miners, J. S., Verble, D. D., Zetterberg, H., Zhao, L., Trotti, L. M., Benameur, K., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13457 · Cited by 20 · see citing works

The "Alzheimer's disease signature": potential perspectives for novel biomarkers

Davinelli, S., Intrieri, M., Russo, C., Costanzo, A. D., Zella, D., Bosco, P., & Scapagnini, G. (2011) · Immunity & Ageing · doi:10.1186/1742-4933-8-7 · Cited by 21 · see citing works

Exosomal Aβ-Binding Proteins Identified by “In Silico” Analysis Represent Putative Blood-Derived Biomarker Candidates for Alzheimer´s Disease

Martins, T. S., Marçalo, R., Ferreira, M., Vaz, M., Silva, R. M., Rosa, I. M., Vogelgsang, J. S., Wiltfang, J., Silva, O. A. B. D. C. E., & Henriques, A. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083933 · Cited by 21 · see citing works

Correlation between Cognitive Impairment and Peripheral Biomarkers - Significance of Phosphorylated Tau and Amyloid-β in Alzheimer’s Disease: A New Insight

Sarkar, S., Bhui, U., Kumar, B., Ashique, S., Kumar, P., Sharma, H., Bhowmick, M., Pal, R., & Kumar, T. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822329981241007105405 · Cited by 20 · see citing works

Neurochemical biomarkers in Alzheimer’s disease and related disorders

Bibl, M., Esselmann, H., & Wiltfang, J. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612455367 · Cited by 20 · see citing works

Phenotype and imaging features associated with APP duplications

Grangeon, L., Charbonnier, C., Zaréa, A., Rousseau, S., Rovelet‐Lecrux, A., Bendetowicz, D., Lemaitre, M., Malrain, C., Quillard‐Muraine, M., Cassinari, K., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01172-2 · Cited by 18 · see citing works

A Consensus in Korea Regarding a Protocol to Reduce Preanalytical Sources of Variability in the Measurement of the Cerebrospinal Fluid Biomarkers of Alzheimer's Disease

Park, S. A., Kang, J.-H., Kang, E., Ki, C., Roh, J. H., Youn, Y. C., Kim, S. Y., & Kim, S. (2015) · Journal of Clinical Neurology · doi:10.3988/jcn.2015.11.2.132 · Cited by 19 · see citing works

Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy

Coppi, E., Ferrari, L., Santangelo, R., Caso, F., Pinto, P., Passerini, G., Comi, G., & Magnani, G. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1644-5 · Cited by 22 · see citing works

Decreased striatal dopamine transporter uptake in the non‐fluent/agrammatic variant of primary progressive aphasia

Gil-Navarro, S., Lomeña, F., Cot, A., Lladó, A., Montagut, N., Castellví, M., Bosch, B., Rami, L., Antonell, A., Balasa, M., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12196 · Cited by 17 · see citing works

Alzheimer’s disease basics: we all should know

Das, S. K. (2025) · Neurological Research · doi:10.1080/01616412.2025.2529560 · Cited by 19 · see citing works

Extracellular Vesicle-Enriched miRNA-Biomarkers Show Improved Utility for Detecting Alzheimer’s Disease Dementia and Medial Temporal Atrophy

Chai, Y. L., Strohm, L., Zhu, Y., Chia, R. S. L., Chong, J. R., Suresh, D. D., Zhou, L. H., Too, H., Hilal, S., Radivoyevitch, T., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230572 · Cited by 19 · see citing works

Neutral polymers as coatings for high resolution electrophoretic separation of Aβ peptides on glass microchips

Mesbah, K., Verpillot, R., Chiari, M., Pallandre, A., & Taverna, M. (2014) · The Analyst · doi:10.1039/c4an01296h · Cited by 16 · see citing works

Tau Protein Alterations Induced by Hypobaric Hypoxia Exposure

Pena, E., Martin-Salamanca, R. S., Alam, S. E., Flores, K., & Arriaza, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020889 · Cited by 16 · see citing works

Biomarker bei Demenzen und anderen neurodegenerativen Erkrankungen

Wiltfang, J., Lewczuk, P., & Otto, M. (2016) · Der Nervenarzt · doi:10.1007/s00115-016-0238-2 · Cited by 15 · see citing works

The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease

Samey, R. A., Antier, D., Mavel, S., Dufour‐Rainfray, D., Balageas, A., Beaufils, É., Emond, P., Foucault‐Fruchard, L., & Chalon, S. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12654 · Cited by 16 · see citing works

A systematic review of amyloid-β peptides as putative mediators of the association between affective disorders and Alzheimer׳s disease

Abbasowa, L., & Heegaard, N. H. H. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.050 · Cited by 15 · see citing works

FTIR Spectroscopy and Blood-Derived Extracellular Vesicles Duo in Alzheimer’s Disease

Martins, T. S., Ferreira, M., Magalhães, S., Leandro, K., de Almeida, L. P., Vogelgsang, J. S., Breitling, B., Hansen, N., Esselmann, H., Wiltfang, J., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231239 · Cited by 15 · see citing works

Imaging and biomarkers for Alzheimer's disease

Allan, C. L., Sexton, C. E., Welchew, D., & Ebmeier, K. P. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.006 · Cited by 15 · see citing works

Soluble amyloid-beta isoforms predict downstream Alzheimer’s disease pathology

Povala, G., Bellaver, B., Bastiani, M. A. D., Brum, W. S., Ferreira, P. C. L., Bieger, A., Pascoal, T. A., Benedet, A. L., Souza, D. O., Araújo, R., et al. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00712-3 · Cited by 13 · see citing works

Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample

Ibach, B., Binder, H., Dragon, M., Poljansky, S., Haen, E., Schmitz, E., Koch, H., Putzhammer, A., Kluenemann, H., Wieland, W. F., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.06.005 · Cited by 67 · see citing works

Amyloid-β(1–42), Total Tau, and Phosphorylated Tau as Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease

Mulder, C., Verwey, N. A., van der Flier, W. M., Bouwman, F. H., Kok, A., van Elk, E. J., Scheltens, P., & Blankenstein, M. A. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2009.130518 · Cited by 332 · see citing works

CSF tau protein andβ‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population

Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 76 · see citing works

Clinical indications for analysis of Alzheimer's disease CSF biomarkers

Engelborghs, S. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.024 · Cited by 20 · see citing works

Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease

Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 219 · see citing works